Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
NCT07117890
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
sunvozertinib 300mg
DRUG:
sunvozertinib 200mg
Sponsor
Fudan University